A Pancreatic Cancer Patient-Derived Xenograft Model for Adoptive Immunotherapy Using Autologous Tumor-Infiltrating Lymphocytes.
作者信息
Leone Valentina, Peschke Katja, Reichert Maximilian
机构信息
Klinik und Poliklinik für Innere Medizin II, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.
Translational Pancreatic Cancer Research Center, Klinik und Poliklinik für Innere Medizin II, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.
出版信息
Gastro Hep Adv. 2022 Aug 31;1(6):1122-1123. doi: 10.1016/j.gastha.2022.08.008. eCollection 2022.
Abstract
摘要
相似文献
1
A Pancreatic Cancer Patient-Derived Xenograft Model for Adoptive Immunotherapy Using Autologous Tumor-Infiltrating Lymphocytes.一种用于过继性免疫治疗的胰腺癌患者来源异种移植模型，采用自体肿瘤浸润淋巴细胞。
Gastro Hep Adv. 2022 Aug 31;1(6):1122-1123. doi: 10.1016/j.gastha.2022.08.008. eCollection 2022.
2
Genetics and Therapeutic Responses to Tumor-Infiltrating Lymphocyte Therapy of Pancreatic Cancer Patient-Derived Xenograft Models.胰腺癌患者来源异种移植模型的遗传学及对肿瘤浸润淋巴细胞治疗的反应
Gastro Hep Adv. 2022 Jul 15;1(6):1037-1048. doi: 10.1016/j.gastha.2022.07.006. eCollection 2022.
3
An autologous humanized patient-derived-xenograft platform to evaluate immunotherapy in ovarian cancer.一种用于评估卵巢癌免疫疗法的自体人源化患者来源异种移植平台。
Gynecol Oncol. 2020 Jan;156(1):222-232. doi: 10.1016/j.ygyno.2019.10.011. Epub 2019 Dec 7.
4
[Clinical application of adoptive immunotherapy by cytotoxic T lymphocytes induced from tumor-infiltrating lymphocytes].肿瘤浸润淋巴细胞诱导的细胞毒性T淋巴细胞过继性免疫治疗的临床应用
Nihon Gan Chiryo Gakkai Shi. 1990 May 20;25(5):978-89.
5
Induction of tumor-specific cytotoxicity in tumor infiltrating lymphocytes by HPV16 and HPV18 E7-pulsed autologous dendritic cells in patients with cancer of the uterine cervix.人乳头瘤病毒16型和18型E7脉冲自体树突状细胞诱导子宫颈癌患者肿瘤浸润淋巴细胞产生肿瘤特异性细胞毒性。
Gynecol Oncol. 2003 May;89(2):271-80. doi: 10.1016/s0090-8258(03)00083-0.
6
Evaluation of the tumoricidal efficacy of adoptive cell transfer using hepatocellular carcinoma-derived organoids.利用肝癌来源类器官评估过继性细胞转移的杀瘤效果。
J Gastrointest Oncol. 2022 Apr;13(2):732-743. doi: 10.21037/jgo-21-715.
7
Depletion of CD4(+)CD25(high) regulatory T cells from tumor infiltrating lymphocytes predominantly induces Th1 type immune response in vivo which inhibits tumor growth in adoptive immunotherapy.从肿瘤浸润淋巴细胞中去除CD4(+)CD25(高)调节性T细胞主要在体内诱导Th1型免疫反应，这在过继性免疫治疗中可抑制肿瘤生长。
Cancer Biol Ther. 2009 Jan;8(1):66-72. doi: 10.4161/cbt.8.1.7131. Epub 2009 Jan 4.
8
Human accessory cells activate fresh, normal, tumor-distant T lymphocytes but not tumor-infiltrating T lymphocytes to lyse autologous tumor cells in a primary cytotoxic T lymphocyte assay in renal cell carcinoma.在肾细胞癌的原发性细胞毒性T淋巴细胞检测中，人类辅助细胞可激活新鲜、正常、远离肿瘤的T淋巴细胞，但不能激活肿瘤浸润性T淋巴细胞来裂解自体肿瘤细胞。
Eur Urol. 2001 Oct;40(4):427-33. doi: 10.1159/000049811.
9
Adoptive cell transfer using autologous tumor infiltrating lymphocytes in gynecologic malignancies.采用自体肿瘤浸润淋巴细胞的过继细胞转移治疗妇科恶性肿瘤。
Gynecol Oncol. 2018 Aug;150(2):361-369. doi: 10.1016/j.ygyno.2018.05.024. Epub 2018 May 24.
10
A phase I clinical trial utilizing autologous tumor-infiltrating lymphocytes in patients with primary hepatocellular carcinoma.一项在原发性肝细胞癌患者中使用自体肿瘤浸润淋巴细胞的I期临床试验。
Oncotarget. 2015 Dec 1;6(38):41339-49. doi: 10.18632/oncotarget.5463.
本文引用的文献
1
Cancer statistics, 2022.癌症统计数据，2022 年。
CA Cancer J Clin. 2022 Jan;72(1):7-33. doi: 10.3322/caac.21708. Epub 2022 Jan 12.
2
Prognostic value of immune factors in the tumor microenvironment of patients with pancreatic ductal adenocarcinoma.免疫因子在胰腺导管腺癌患者肿瘤微环境中的预后价值。
BMC Cancer. 2021 Nov 10;21(1):1197. doi: 10.1186/s12885-021-08911-4.
3
Pancreatic Cancer and Immunotherapy: A Clinical Overview.胰腺癌与免疫疗法：临床概述
Cancers (Basel). 2021 Aug 17;13(16):4138. doi: 10.3390/cancers13164138.
4
Challenges and perspectives for immunotherapy in oesophageal cancer: A look to the future (Review).免疫疗法在食管癌治疗中的挑战与展望：展望未来（综述）。
Int J Mol Med. 2021 Jun;47(6). doi: 10.3892/ijmm.2021.4930. Epub 2021 Apr 13.
5
Estimated Projection of US Cancer Incidence and Death to 2040.预估 2040 年美国癌症发病与死亡人数。
JAMA Netw Open. 2021 Apr 1;4(4):e214708. doi: 10.1001/jamanetworkopen.2021.4708.
6
The Outcome of TIL Expansion Is Highly Influenced by Spatial Heterogeneity of the Tumor T-Cell Repertoire and Differences in Intrinsic Growth Capacity between T-Cell Clones.肿瘤浸润淋巴细胞（TIL）扩增的结果受到肿瘤T细胞受体库的空间异质性以及T细胞克隆之间内在生长能力差异的高度影响。
Clin Cancer Res. 2020 Aug 15;26(16):4289-4301. doi: 10.1158/1078-0432.CCR-19-3845. Epub 2020 Apr 17.
7
Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial.接受分子谱分析后接受匹配治疗的胰腺癌患者的总生存期：Know Your Tumor 登记试验的回顾性分析。
Lancet Oncol. 2020 Apr;21(4):508-518. doi: 10.1016/S1470-2045(20)30074-7. Epub 2020 Mar 2.
8
Checkpoint inhibitors in pancreatic cancer.胰腺癌的检查点抑制剂。
Cancer Treat Rev. 2019 Aug;78:17-30. doi: 10.1016/j.ctrv.2019.06.005. Epub 2019 Jun 27.
9
Cellular determinants and therapeutic implications of inflammation in pancreatic cancer.胰腺癌中炎症的细胞决定因素和治疗意义。
Pharmacol Ther. 2019 Sep;201:202-213. doi: 10.1016/j.pharmthera.2019.05.012. Epub 2019 May 31.
10
Immunotherapy in colorectal cancer: rationale, challenges and potential.结直肠癌的免疫治疗：原理、挑战与潜能。
Nat Rev Gastroenterol Hepatol. 2019 Jun;16(6):361-375. doi: 10.1038/s41575-019-0126-x.
Zotero 插件